Citi halts purchase of Ascendis with $178 short-term party from Investing.com

Citigroup has a free sale price for the Ascendis Pharma (NASDAQ:ASND) assets and the best price is $178.00. This estimate will take place in the forecourt of the study presentation during Ascendis at the European Society for Medical Oncology (ESMO) conference, September 13-17. I think I did the Phase 1/2 Study IL-Believe on TransCon IL-2 β/γ, because the treatment was done in patients with platinum-resistant Eierstockkrebs (PROC).

The ESMO presentation is based on 18 studies that have now been published on 14 for the analysis of the effectiveness. Four patients were excluded on the basis of progression of the disease or death for the time being.

If the patient had a clinical examination of 29%, four people were involved. Although they have the best partial remissions, the others are not the best. If the main features of the disease, thrombocytopenia, neutropenia and anemia occur.

The ESMO conference helped Citi compete with data from its Ascendis therapy for achondroplasia, TransCon CNP.

The analysts of Citigroup look forward to positioning Ascendis Pharma and their external companies for the existing data distribution. The risk-return relationship was considered one of the biggest challenges, was the market war and the program and an improved view for the borrowed Ascendis study and the broader mirror of the competition.

In other active news from Ascendis Pharma, clinical studies have been conducted in PROC patients, which became known in the Phase 1/2 IL-Believe study with TransCon IL-2 β/γ.

These positive messages could be a reaction from an analyst rating agency: Citi believes its purchase recommendation at TD Cowen which gets a “Buy” rating and an Oppenheimer bumped Ascendis Pharma from “Perform” to “Outperform” high.

Ascendis Pharma’s financial sector for the second quarter of 2024 has shown a great picture. Despite a reversal of the SKYTROFA Umsätze on the basis of adjustments and higher sales restrictions, the company was able to conclude a new financing agreement with Royalty Pharma worth 150 million dollars. A product has been found that uses YORVIPATH for hypoparathyroidism in the washing of the disease in the US.

The Forschungs- und Entwicklungkosten of the Unternehmens have decreased over time to 21%, which causes the Vertriebs- und Verwaltungkosten on the ground gestiegener Personalaufwendungen zunahmmen. Zum Quartalsende versügte Ascendis Pharma über liquide Mittel in Hoge von 259 Millionen Euro. For the company’s 2024 forecast, a SKYTROFA-Umsatz is worth 220 and 240 million euros.

This description can be performed by the intelligent intelligence. Weitere Informationen entnehmen Sie bitte unseren Nutzungsbedingungen.